Intravenous methylprednisolone for multiple sclerosis in relapse.
A randomised comparison is made between methylprednisolone, 1 g intravenously daily for 7 days, and a standard ACTH regime for the treatment of multiple sclerosis in acute relapse. It is found that methylprednisolone produces a more rapid clinical improvement than ACTH but confers no longer term benefit when the two treatments are compared at 3 months. It is proposed that intravenous methylprednisolone does have a role to play in the management of a patient with an acute relapse of multiple sclerosis.
Barnes
M P
MP
Bateman
D E
DE
Cleland
P G
PG
Dick
D J
DJ
Walls
T J
TJ
Newman
P K
PK
Saunders
M
M
Tilley
P J
PJ
D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011897:Random Allocation; D012008:Recurrence; D013997:Time Factors
D000324:Adrenocorticotropic Hormone; D008775:Methylprednisolone